The human antibody repertoire, or reactome, is a vast and dynamic network of antibody-antigen interactions that plays a crucial role in health and disease. Understanding the complexity of this network [….]
Spotlight Your Start-up: Apply to Compete in the 9th Annual Crab Trap Competition July 17, 2024 Get ready to showcase your start-up at the BioHealth Capital Region Week! The 9th [….]
Gene Mack Appointed Interim CEO of Gain Therapeutics, Inc. Gain Therapeutics, Inc. a clinical-stage biotechnology company at the forefront of discovering and developing the next generation of allosteric small molecule [….]
NextStep Robotics Wins Pitch Dingman Competition Grand Prize, Announces New Board Members NextStep Robotics is a Baltimore, MD-based therapeutic device and robotics company creating advanced solutions to alleviate and eventually [….]
Host cell proteins (HCPs) are process-related impurities deriving from host organisms used for the expression of biological products like recombinant proteins or viral vectors. HCPs, if not adequately controlled, can [….]
John Mumm is a serial biotechnology entrepreneur who, as a young researcher, demonstrated the importance of the cytokine, interleukin -10 (IL-10), in activating the immune system to destroy tumors. That research led to the use of Pegylated IL-10 to treat patients with pancreatic cancer and other solid tumors through his work at ARMO Biosciences, a company he founded and was later acquired by Eli Lilly in 2018.
Trevena Inc.’s novel AT1 receptor-selective agonist TRV027 will be included in an international, adaptive Phase II/III study as a potential treatment for COVID-19 patients. The study is being supported by multiple international governments and global research organizations.
ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a three-year, $9.86 million task order contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to manage and operate its HIV Reagent Program, formerly known as the AIDS Reagent Program. ATCC is tasked to supply the HIV/AIDS research community with no-cost, high-quality materials supporting the development and evaluation of therapeutics, vaccines, and diagnostics.
BioFactura Awarded $67.4 Million Advanced Development Contract for its Smallpox Biodefense Therapeutic Frederick, Maryland, September 26, 2019: BioFactura, Inc. today announced a contract awarded by the Biomedical Advanced Research and [….]
